Sanofi invests in French vaccine production facility

Global healthcare company Sanofi has announced it is investing €170 million to expand its vaccine manufacturing site in Val de Reuil, France.

This expansion will enable the company’s Vaccines global business unit, Sanofi Pasteur, to expand the supply of its quadrivalent influenza vaccine, VaxigripTetra, to up to 70 countries in six continents.

“Influenza continues to be a major public health problem around the world, causing serious complications, hospitalisations and deaths, mostly for certain high-risk individuals,” said David Loew, executive vice president, Sanofi, and head of Sanofi Pasteur. “As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur's ability to tackle this underestimated health challenge.”

“This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions,” added Philippe Luscan, executive vice president, Global Industrial Affairs, Sanofi. “Our investment underlines Sanofi's intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets.”

The expansion is planned to be completed by 2021, subject to relevant health authority approvals, and production of vaccines in this new facility is anticipated to begin in 2022.